Trevi Therapeutics Announces 2024 Annual Meeting of Stockholders on June 13
Ticker: TRVI · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1563880
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Stockholders, Director Election, Auditor Ratification
TL;DR
<b>Trevi Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, with key votes on director elections and auditor ratification.</b>
AI Summary
Trevi Therapeutics, Inc. (TRVI) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Annual Meeting to be held virtually on June 13, 2024, at 12:30 p.m. ET. Stockholders of record as of April 15, 2024, are eligible to vote. Key agenda items include election of three Class II directors and ratification of Ernst & Young LLP as independent auditor. Virtual attendance, electronic voting, and question submission available via proxydocs.com/TRVI. No physical meeting location; attendance is exclusively online.
Why It Matters
For investors and stakeholders tracking Trevi Therapeutics, Inc., this filing contains several important signals. This meeting is a crucial forum for shareholders to exercise their voting rights on corporate governance matters, including director appointments and auditor oversight. The virtual format allows for broader participation and accessibility for stockholders, while also streamlining the meeting process for the company.
Risk Assessment
Risk Level: low — Trevi Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational changes indicated, thus posing low risk.
Analyst Insight
Stockholders should review the director nominees and auditor ratification proposals to make informed voting decisions before the June 13th meeting.
Key Numbers
- June 13, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
- 12:30 p.m. ET — Annual Meeting Time (Time of the 2024 Annual Meeting of Stockholders.)
- April 15, 2024 — Record Date (Date to determine stockholder eligibility to vote.)
- 3 — Directors to be Elected (Number of Class II directors to be elected.)
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
- June 13, 2024 (date) — Date of the 2024 Annual Meeting of Stockholders.
- April 15, 2024 (date) — Record date for determining stockholders eligible to vote.
- Ernst & Young LLP (company) — Proposed independent registered public accounting firm.
- Class II directors (other) — Directors to be elected at the meeting.
FAQ
When did Trevi Therapeutics, Inc. file this DEF 14A?
Trevi Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Trevi Therapeutics, Inc. (TRVI).
Where can I read the original DEF 14A filing from Trevi Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Trevi Therapeutics, Inc..
What are the key takeaways from Trevi Therapeutics, Inc.'s DEF 14A?
Trevi Therapeutics, Inc. filed this DEF 14A on April 26, 2024. Key takeaways: Annual Meeting to be held virtually on June 13, 2024, at 12:30 p.m. ET.. Stockholders of record as of April 15, 2024, are eligible to vote.. Key agenda items include election of three Class II directors and ratification of Ernst & Young LLP as independent auditor..
Is Trevi Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Trevi Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational changes indicated, thus posing low risk.
What should investors do after reading Trevi Therapeutics, Inc.'s DEF 14A?
Stockholders should review the director nominees and auditor ratification proposals to make informed voting decisions before the June 13th meeting. The overall sentiment from this filing is neutral.
How does Trevi Therapeutics, Inc. compare to its industry peers?
Trevi Therapeutics operates in the pharmaceutical preparations industry, focusing on the development of treatments for specific medical conditions.
Are there regulatory concerns for Trevi Therapeutics, Inc.?
The filing is a standard proxy statement (DEF 14A) required by the SEC for public companies to solicit shareholder votes.
Industry Context
Trevi Therapeutics operates in the pharmaceutical preparations industry, focusing on the development of treatments for specific medical conditions.
Regulatory Implications
The filing is a standard proxy statement (DEF 14A) required by the SEC for public companies to solicit shareholder votes.
What Investors Should Do
- Review the biographies and qualifications of the Class II director nominees.
- Evaluate the proposal to ratify Ernst & Young LLP as the independent auditor for fiscal year 2024.
- Ensure timely voting by the record date of April 15, 2024, for the June 13, 2024, Annual Meeting.
Key Dates
- 2024-06-13: 2024 Annual Meeting of Stockholders — Shareholders will vote on director elections and auditor ratification.
- 2024-04-15: Record Date — Determines eligibility of stockholders to vote at the Annual Meeting.
Year-Over-Year Comparison
This is the initial filing for the 2024 Annual Meeting of Stockholders, providing details on upcoming votes and meeting procedures.
Filing Stats: 4,824 words · 19 min read · ~16 pages · Grade level 11.1 · Accepted 2024-04-26 16:38:38
Filing Documents
- trvi_-_def_14a_2024.htm (DEF 14A) — 722KB
- img38854683_0.jpg (GRAPHIC) — 54KB
- img38854683_1.jpg (GRAPHIC) — 20KB
- img38854683_2.jpg (GRAPHIC) — 54KB
- img38854683_3.jpg (GRAPHIC) — 20KB
- img38854683_4.jpg (GRAPHIC) — 224KB
- img38854683_5.jpg (GRAPHIC) — 127KB
- 0000950170-24-049234.txt ( ) — 1402KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 17 TRANSACTIONS WITH RELATED PERSONS 23 PRINCIPAL STOCKHOLDERS 27 REPORT OF THE AUDIT COMMITTEE 30 HOUSEHOLDING 31 STOCKHOLDER PROPOSALS 31 OTHER MATTERS 31 TREVI THERAPEUTICS, INC. 195 Church Street, 16 th Floor New Haven, CT 06510 203-304-2499 PROXY ST ATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS to be held June 13, 2024 This proxy statement and the proxy card contain information about the 2024 Annual Meeting of Stockholders of Trevi Therapeutics, Inc., or the Annual Meeting, to be held exclusively online via the Internet as a virtual web conference at https://www.proxydocs.com/TRVI on Thursday, June 13, 2024 at 12:30 p.m. Eastern Time. You will be able to attend the Annual Meeting online, vote your shares electronically during the meeting and submit questions during the meeting by visiting https://www.proxydocs.com/TRVI. There will not be a physical meeting location and you will not be able to attend the Annual Meeting in person. Your vote is very important to us. Whether or not you plan to attend the Annual Meeting online, your shares should be represented and voted. The Board of Directors of Trevi is using this proxy statement and the proxy card to solicit proxies for use at the Annual Meeting. In this proxy statement, unless expressly stated otherwise or the context otherwise requires, the use of “Trevi,” “our,” “we” or “us” refers to Trevi Therapeutics, Inc. and its wholly owned subsidiary. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held on June 13, 2024: This proxy statement and our 2023 Annual Report to Stockholders are available for viewing, printing and downloading at https://www.proxydocs.com/TRVI. A copy of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission, or SEC, except fo
: Gender Identity
Part I: Gender Identity Directors 2 5 0 0
: Demographic Background
Part II: Demographic Background African American or Black 0 0 0 0 Alaskan Native or Native American 0 0 0 0 Asian 0 0 0 0 Hispanic or Latinx 0 0 0 0 Native Hawaiian or Pacific Islander 0 0 0 0 White 2 5 0 0 Two or More Races or Ethnicities 0 0 0 0 LGBTQ+ 0 Did Not Disclose Demographic Background 0 Our Board Diversity Matrix as of May 1, 2023 can be found in the proxy statement for our 2023 Annual Meeting of Stockholders, filed with the SEC on May 1, 2023. 6 Nominees for Election as Class II Directors Biographical information,